Why is Nektar Therapeutics stock climbing today?

Nektar Therapeutics stock is currently climbing following a significant legal development. The company has secured a $90M jury verdict in a case against Lilly. This financial award has triggered a positive reaction in the market, leading to the rise in the share price of Nektar Therapeutics. The stock's upward movement is directly attributed to the outcome of this specific jury verdict, reflecting investor confidence in the company's recent legal success against the pharmaceutical competitor.